Celltrion Pharm Inc.

South Korean exporters are bracing for a tough year with their profits poised to languish, hit by the strong won, amid expectations for a rebound in...

South Korea's biopharmaceutical firm Celltrion Inc. has completed the $278 million acquisition of Takeda Pharmaceutical Company Ltd's primary care a...

South Korea’s biopharmaceutical firm Celltrion Inc. can unveil an antibody treatment by around the end of the year that is able to kill the COVI...

South Korean biosimilar maker Celltrion Inc's operating profit topped market expectations by more than 20% in the third quarter, hitting a record high...

Seo Jung-jin, founder and chairman of South Korea’s biosimilar maker Celltrion Group, said on Oct. 6 that he is in talks with a number of global...

South Korea’s Celltrion Inc. and its affiliates are expected to post robust operating profits this year on the back of strong sales of Remsima a...

South Korea’s Celltrion Inc. on Sept. 10 rebutted J.P. Morgan’s massive downgrade of its target price for the biopharmaceutical company. T...

Biosimilar maker Celltrion Inc. has agreed to develop a tablet-type treatment for autoimmune diseases jointly with the UK biotech startup Intract Phar...

One Equity Partners (OEP), a New York based private equity firm, unloaded its remaining shares in Celltrion Healthcare valued at approximately 31...

Hanmi Pharmaceutical said on Monday that it had signed an agreement with Euclid Medical Products, a company specializing in manufacturing drug dis...